

Polatuzumab ELISA Kit

Summary

Catalog No.	KDE26302
Alternative Names	ACD79B-VCMAAE, DCDS4501A, FCU2711, RO5541077-000, polatuzumab vedotin-piiq, CAS: 1313206-42-6
Stability and Storage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection method	Colorimetric
Sample type	Plasma, Serum
Assay type	Quantitative
Sensitivity	0.156 µg/ml
Range	0.31-5 µg/mL
Recovery	80-120%
Shipping	2-8 °C
Note	For Research Use Only.

Background

Polatuzumab vedotin is an antibody-drug conjugate formed by a CD79b antibody conjugated to the highly cytotoxic agent monomethyl auristatin E by means of a cleavable linker. Following significant clinical efficacy in R/R DLBCL, polatuzumab vedotin was granted accelerated Food and Drug Administration (FDA) approval in combination with bendamustine plus rituximab for patients who have failed at least two prior therapies. Other clinical studies involving polatuzumab vedotin in combination

Recombinant Proteins & Antibodies

with other therapy regimens are also under evaluation for previously untreated DLBCL patients.

Precision

CV<20%

Data Image
